284 related articles for article (PubMed ID: 26953344)
1. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.
Suryo Rahmanto Y; Jung JG; Wu RC; Kobayashi Y; Heaphy CM; Meeker AK; Wang TL; Shih IeM
J Biol Chem; 2016 Apr; 291(18):9690-9. PubMed ID: 26953344
[TBL] [Abstract][Full Text] [Related]
2. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
3. ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT.
Bui CB; Le HK; Vu DM; Truong KD; Nguyen NM; Ho MAN; Truong DQ
Mol Carcinog; 2019 Nov; 58(11):1998-2007. PubMed ID: 31365169
[TBL] [Abstract][Full Text] [Related]
4. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
6. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
7. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B; Wang TL; Shih IeM
Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
[TBL] [Abstract][Full Text] [Related]
8. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
9. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
10. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations and telomeres during tumorigenesis.
Lorbeer FK; Hockemeyer D
Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
14. CTCF mediates the TERT enhancer-promoter interactions in lung cancer cells: identification of a novel enhancer region involved in the regulation of TERT gene.
Eldholm V; Haugen A; Zienolddiny S
Int J Cancer; 2014 May; 134(10):2305-13. PubMed ID: 24174344
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
[TBL] [Abstract][Full Text] [Related]
16. E2F-1 represses transcription of the human telomerase reverse transcriptase gene.
Crowe DL; Nguyen DC; Tsang KJ; Kyo S
Nucleic Acids Res; 2001 Jul; 29(13):2789-94. PubMed ID: 11433024
[TBL] [Abstract][Full Text] [Related]
17. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
18. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.
Guan B; Gao M; Wu CH; Wang TL; Shih IeM
Neoplasia; 2012 Oct; 14(10):986-93. PubMed ID: 23097632
[TBL] [Abstract][Full Text] [Related]
20. Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas.
Zhang Y; Calado R; Rao M; Hong JA; Meeker AK; Dumitriu B; Atay S; McCormick PJ; Garfield SH; Wangsa D; Padilla-Nash HM; Burkett S; Zhang M; Kunst TF; Peterson NR; Xi S; Inchauste S; Altorki NK; Casson AG; Beer DG; Harris CC; Ried T; Young NS; Schrump DS
PLoS One; 2014; 9(7):e101010. PubMed ID: 24983628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
